Management of antiviral drug resistance in chronic hepatitis B

Table 3 Antiviral drug efficacies in rescue settings

Virologic, serologic, and biochemical responses	ADV monotherapy[76]	ETV monotherapy[45,46]	ADV + LAM combination therapy[43]	ADV + LdT combination therapy[77]	ADV + ETV combination therapy[78,79]
Patients with undetectable HBV-DNA (%)
1 yr	22.8	54.5	61	70.3	88.8
2 yr	48.9	50.0	70		97.8
3 yr	56.8		79
4 yr	60.3		82
5 yr	60.3
Cumulative probability of genotypic resistance (%)
1 yr	4.4	6	0.7	0	0
2 yr	18.4	15	0.9		0
3 yr	34.3	36	1.3
4 yr	52.3	46
5 yr	65.6	51
Cumulative probability of HBeAg seroconversion (%)
1 yr	7.3	0		9.67	15.6
2 yr	12.7	0			26.7
3 yr	15.0		24
4 yr	17.0
5 yr	17.0
Cumulative probability of ALT normalization (%)
1 yr	80.3	77.3	84	64	100
2 yr	83.2	80	87		100
3 yr	86.7		89
4 yr	88.2
5 yr	88.2

ADV: Adefovir; ETV: Entecavir; LAM: Lamivudine; LdT: Telbivudine; TDF: Tenofovir; HBV-DNA: Hepatitis B virus deoxynucleic acid; HBeAg: Hepatitis B e antigen; ALT: Alanine aminotransferase.